P

Pulike Biological Engineering Inc
SSE:603566

Watchlist Manager
Pulike Biological Engineering Inc
SSE:603566
Watchlist
Price: 12.7 CNY -4.37% Market Closed
Market Cap: 4.4B CNY
Have any thoughts about
Pulike Biological Engineering Inc?
Write Note

Pulike Biological Engineering Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pulike Biological Engineering Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
P
Pulike Biological Engineering Inc
SSE:603566
Operating Income
ÂĄ97.7m
CAGR 3-Years
-29%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Operating Income
ÂĄ2.6B
CAGR 3-Years
-2%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Operating Income
ÂĄ3.4B
CAGR 3-Years
17%
CAGR 5-Years
20%
CAGR 10-Years
22%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Operating Income
ÂĄ5.8B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Operating Income
ÂĄ4B
CAGR 3-Years
-1%
CAGR 5-Years
14%
CAGR 10-Years
3%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Operating Income
-ÂĄ749.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pulike Biological Engineering Inc
Glance View

Market Cap
4.4B CNY
Industry
Pharmaceuticals

Pulike Biological Engineering, Inc. engages in the research, development, manufacturing and sale of biological products for animals, chemical drugs and Chinese veterinary drugs. The company is headquartered in Luoyang, Henan and currently employs 1,809 full-time employees. The company went IPO on 2015-05-18. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The firm's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.

Intrinsic Value
20.86 CNY
Undervaluation 39%
Intrinsic Value
Price
P

See Also

What is Pulike Biological Engineering Inc's Operating Income?
Operating Income
97.7m CNY

Based on the financial report for Sep 30, 2024, Pulike Biological Engineering Inc's Operating Income amounts to 97.7m CNY.

What is Pulike Biological Engineering Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-1%

Over the last year, the Operating Income growth was -60%. The average annual Operating Income growth rates for Pulike Biological Engineering Inc have been -29% over the past three years , -1% over the past five years .

Back to Top